865-P: Metformin Reduces Insulin Dose and Visceral Fat Accumulation, and Increases GDF15 without Reducing Insulin Resistance in Adults with Type 1 Diabetes—A 26-Week, Randomized, Double-Blind Placebo-Controlled Trial (INTIMET)

Abstract

Insulin resistance is a cardiovascular (CV) risk factor in type 1 diabetes (T1D). The effect of metformin on liver and muscle insulin resistance has not been studied in adults with T1D. We recruited 40 adults with T1D (HbA1c 7.5±0.9% [58±10mmol/mol], diabetes duration 22.9±8.9 years, age 37.4±8.8 years, 60% male, BMI 26.4±3.8 kg/m2). Twenty age, gender and BMI matched controls without diabetes were studied at baseline only. Subjects with T1D were randomized to metformin XR 1500mg daily or placebo for 26 weeks. At baseline and end of treatment, subjects completed two-step hyperinsulinemic-euglycemic clamps with 6,6-2H2 glucose to measure insulin sensitivity at liver (endogenous glucose produc..